J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Inotsume, N
Right arrow Articles by Sato, T
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Inotsume, N
Right arrow Articles by Sato, T
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Articles

The inhibitory effect of probenecid on renal excretion of famotidine in young, healthy volunteers

N Inotsume, M Nishimura, M Nakano, S Fujiyama, and T Sato

Effects of coadministration of probenecid on pharmacokinetic behaviors of famotidine, an H2-receptor antagonist, after oral administration, were studied in eight young, healthy volunteers. They received an oral 20 mg dose of famotidine with and without coadministration of oral 1500 mg doses of probenecid. The mean area under the serum famotidine concentration-time curve up to 10 hours was increased by coadministration of probenecid from 424 +/- 19 (SEM) to 768 +/- 39 ng.hr/ml. The mean urinary excretion rate of unchanged famotidine, the mean amount of unchanged famotidine excreted in urine up to 24 hours and mean renal clearance were decreased by coadministration of probenecid. The mean tubular secretion clearance of famotidine was decreased from 196.2 +/- 21.4 to 22.0 +/- 4.2 ml/min. These data suggest that probenecid, which is a classical inhibitor of renal tubular secretion of organic anions, inhibits the renal tubular secretion of famotidine, which exists partly in a cationic form under physiological pH conditions.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
Y. Nozaki, H. Kusuhara, T. Kondo, M. Hasegawa, Y. Shiroyanagi, H. Nakazawa, T. Okano, and Y. Sugiyama
Characterization of the Uptake of Organic Anion Transporter (OAT) 1 and OAT3 Substrates by Human Kidney Slices
J. Pharmacol. Exp. Ther., April 1, 2007; 321(1): 362 - 369.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
H. Tahara, H. Kusuhara, M. Chida, E. Fuse, and Y. Sugiyama
Is the Monkey an Appropriate Animal Model to Examine Drug-Drug Interactions Involving Renal Clearance? Effect of Probenecid on the Renal Elimination of H2 Receptor Antagonists
J. Pharmacol. Exp. Ther., March 1, 2006; 316(3): 1187 - 1194.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
O. Q. P. Yin, B. Tomlinson, and M. S. S. Chow
Variability in Renal Clearance of Substrates for Renal Transporters in Chinese Subjects
J. Clin. Pharmacol., February 1, 2006; 46(2): 157 - 163.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
D. L. Bourdet, J. B. Pritchard, and D. R. Thakker
Differential Substrate and Inhibitory Activities of Ranitidine and Famotidine toward Human Organic Cation Transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3)
J. Pharmacol. Exp. Ther., December 1, 2005; 315(3): 1288 - 1297.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
H. Tahara, H. Kusuhara, H. Endou, H. Koepsell, T. Imaoka, E. Fuse, and Y. Sugiyama
A Species Difference in the Transport Activities of H2 Receptor Antagonists by Rat and Human Renal Organic Anion and Cation Transporters
J. Pharmacol. Exp. Ther., October 1, 2005; 315(1): 337 - 345.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1990 by the American College of Clinical Pharmacology